Nov 10 (Reuters) - Valeant Pharmaceutical International Inc :
* Moody's - Valeant's deleveraging focus is credit positive
* Moody's - Valeant Pharmaceutical's focus on deleveraging is credit positive in light of challenges facing its dermatology and hospital businesses
* Moody's on Valeant - "there is no impact on the existing ratings including the Ba3 corporate family rating and stable rating outlook"
* Moody's - despite weaker sales in dermatology,neurology, Valeant's cash flow to remain substantial,supporting management's commitment to deleveraging
* Source: (http://bit.ly/1MJ684G)
* Further company coverage VRX.TO